Both in Pharmaceuticals
Upstream Bio vs Eledon Pharmaceuticals
Over the past year UPB returned −86.5% and ELDN returned −30.9%; their daily moves had a correlation of 0.17.
UPB −86.5% ELDN −30.9%Growth of $1, one year, split-adjusted
| Metric | UPB | ELDN |
|---|---|---|
| Price | $2.99 | $2.30 |
| Market cap | $163.8M | $186.9M |
| Today | +6.79% | +1.77% |
| 1 month | −42.4% | −15.4% |
| 6 months | −68.9% | −35.9% |
| Year to date | −89.0% | +52.3% |
| 1 year | −86.6% | −34.1% |
| Revenue growth (YoY) | −17.5% | — |
| Gross margin | 100.0% | — |
| Net margin | −5136.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 51.9× | — |
| Net cash | $261.3M | $88.8M |
| Dividend yield | — | — |
| Volatility (60d) | 78.7% | 44.3% |
| Short % of float | 13.3% | 9.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).